SIGA Technologies Inc. (SIGA) Takes Steps toward FDA Approval for its Lead Smallpox Antiviral
SIGA Technologies Inc. (NASDAQ: SIGA) announced it has launched an initiative to produce DNA registration batches of its leading smallpox antiviral, ST-246. The company specializes in the development of pharmaceutical agents effective against biowarfare pathogens. For the past few months, the company has consulted with the FDA to choose its final chemical formulation for large-scale production, and has chosen the market image and packaging needed to commercialize the material. “Now that we have submitted to FDA our package supporting emergency use authorization for ST-246 and have successfully completed a multiple ascending dose human clinical safety trial, we are moving to…